To install StudyMoose App tap and then “Add to Home Screen”
Save to my list
Remove from my list
The Medicines Company faces a critical decision regarding the launch of Angiomax, a recent drug acquisition intended to revolutionize anticoagulant therapy for patients undergoing angioplasty. However, the challenge lies in determining the optimal pricing strategy for Angiomax, given the dominance of the low-cost heparin in the market. This essay explores the context, recommended pricing, strategic rationale, and product positioning for Angiomax, aiming to guide the Medicines Company in successfully navigating this crucial launch during a period of financial instability.
The Medicines Company finds itself in a precarious situation, heavily reliant on the success of Angiomax after the setback of an unsuccessful IS-159 acquisition.
Compounding this, the company is under scrutiny from public investors due to a sharp decline in stock prices. Moreover, external pressures from managed care organizations and government entities intensify, demanding a reduction in drug prices. In this scenario, strategic pricing of Angiomax becomes imperative to not only ensure the financial viability of the Medicines Company but also to deliver a robust value proposition to hospital pharmacists and cardiologists, pivotal stakeholders whose buy-in is essential for the drug's success.
To establish a fair price for Angiomax, it is essential to evaluate the value it offers to hospital pharmacists.
4.8 (298)
“ Professor Brandson did an amazing job! He got the assignment done early and it was exactly what was needed. ”
Clinical trials demonstrate Angiomax's superiority over heparin for high and very high-risk patients undergoing angioplasty. The pricing calculation involves estimating the average impact on angioplasty costs for hospitals when replacing heparin with Angiomax. The analysis, detailed in Table 1 of the Appendix, indicates an average savings of 4.67 per patient.
Considering an average requirement of 1.45 doses of Angiomax per patient, the recommended price is $498.39 per dose, aligning with the budget constraints of pharmacists.
This pricing recommendation ensures a balance between affordability for pharmacists and covering production costs for the Medicines Company.
The Medicines Company should adopt a consumer value-based pricing approach, emphasizing the added value for high and very high-risk patient procedures. This strategy surpasses cost-plus or competitive parity pricing, providing a more accurate assessment of Angiomax's demand and potential profitability. Competitive parity pricing, in particular, would force the company to undersell Angiomax, jeopardizing profits and market positioning.
At the suggested price of $498.39, employing a skimming pricing strategy is advisable, enabling the Medicines Company to recoup production costs and position Angiomax as a premium product. The target customer segment comprises the 38% of doctors dissatisfied or weakly satisfied with heparin, capable of influencing pharmacists to invest in a more effective drug. This approach allows the company to capture significant profits initially, with the option to adjust prices as new competitors enter the market, ensuring long-term sustainability.
An alternative strategy, penetration pricing, could be considered for the early stages to appeal to budget-conscious pharmacists and skeptical doctors. However, the challenge lies in potential difficulties in raising prices later to cover production costs adequately.
Effectively communicating Angiomax's value proposition is crucial for a successful launch. Two key factors bolster this communication. Firstly, Angiomax holds a patent, providing protection against direct competition until 2010. Secondly, clinical trial results highlight significant benefits, including a 33.33% reduction in deaths, 27% fewer heart attacks, a 15% decrease in the need for repeat angioplasty, and a remarkable 66% reduction in major bleeding incidents.
Leveraging these results, the sales teams should target hospital pharmacists with a focus on economic benefits and cardiologists emphasizing reduced side effects and overall effectiveness. Marketing efforts, particularly in medical publications, trade shows, and targeted educational channels, should reinforce Angiomax's premium positioning. With these strategies, the Medicines Company can instill confidence in its key stakeholders and pave the way for Angiomax to become a cornerstone in anticoagulant therapy.
In conclusion, the strategic pricing of Angiomax holds the key to the Medicines Company's success during a challenging period. The recommended price of $498.39 per dose aligns with the economic considerations of hospital pharmacists while ensuring the company's profitability. Adopting a consumer value-based pricing approach and utilizing a skimming strategy target the right customer segment and position Angiomax as a premium product.
The launch and positioning efforts should leverage the product's patent protection and the compelling clinical trial results to create a robust narrative of Angiomax's superiority. By carefully navigating these strategic elements, the Medicines Company can not only overcome its current financial instability but also establish Angiomax as a pioneering solution in the field of anticoagulant therapy.
Strategic Pricing for Angiomax: Medicines Company. (2016, Apr 27). Retrieved from https://studymoose.com/the-medicines-company-and-angiomax-case-analysis-essay
👋 Hi! I’m your smart assistant Amy!
Don’t know where to start? Type your requirements and I’ll connect you to an academic expert within 3 minutes.
get help with your assignment
